Update in Diuretic Therapy: Clinical Pharmacology
| Autor: | D. Craig Brater |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Liver Cirrhosis
Nephrotic Syndrome Cirrhosis medicine.medical_treatment Pharmacology law.invention chemistry.chemical_compound Sodium Potassium Chloride Symporter Inhibitors Pharmacokinetics law medicine Edema Humans Renal Insufficiency Diuretics Heart Failure Clinical pharmacology business.industry medicine.disease chemistry Nephrology Pharmacodynamics Heart failure Spironolactone Diuretic business Nephrotic syndrome |
| Zdroj: | Seminars in Nephrology. 31:483-494 |
| ISSN: | 0270-9295 |
| DOI: | 10.1016/j.semnephrol.2011.09.003 |
| Popis: | All diuretics except spironolactone exert their effects from the lumen of the nephron. Thus, to exert an effect, they must reach the urine. Pharmacokinetics (PK) describes this access. Different edematous disorders can affect access to this site of action and therein affect response to a diuretic. In addition, once a diuretic reaches the site of action, a response ensues. The characteristics of this response that can be affected by a patient's clinical condition are described by the pharmacodynamics (PD) of a diuretic. To understand the mechanisms of abnormal response to a diuretic one must dissect its PK and PD in different edematous disorders. For example, in patients with renal insufficiency, the mechanism of poor diuretic response is PK. In contrast, in patients with cirrhosis or in those with congestive heart failure, it is PD. In patients with nephrotic syndrome, both PK and PD are operative. These different mechanisms mandate differences in therapeutic strategy, as explained in this article. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|